US pharmaceutical company Bristol-Myers Squibb will sell its new schizophrenia treatment in Britain for $22,500 a year, the same price as its US version, as governments on both sides of the Atlantic seek to reduce drug costs.
2025-09-22
US pharmaceutical company Bristol-Myers Squibb will sell its new schizophrenia treatment in Britain for $22,500 a year, the same price as its US version, as governments on both sides of the Atlantic seek to reduce drug costs.
